BI 2536 , ≥98% , 755038-02-9
CAS NO.：755038-02-9
Empirical Formula: C28H39N7O3
Molecular Weight: 521.65
MDL number: MFCD10565924
EINECS: 1308068-626-2
| Pack Size | Price | Stock | Quantity |
| 5MG | RMB490.40 | In Stock |
|
| 10MG | RMB904.80 | In Stock |
|
| 50MG | RMB2962.40 | In Stock |
|
| 100MG | RMB5614.40 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Density | 1.28 |
| storage temp. | Keep in dark place,Sealed in dry,Store in freezer, under -20°C |
| solubility | Soluble in DMSO (up to 20 mg/ml) or in Ethanol (up to 25 mg/ml) |
| form | Yellow powder. |
| pka | 14.09±0.20(Predicted) |
| color | Off-white |
| Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months. |
Description and Uses
BI 2536 (755038-02-9) was originally reported as a potent (IC50’s Plk1 = 0.83nM, Plk2 = 3.5nM and Plk3 = 9.0nM)1?and selective2?Polo-like kinase inhibitor?that caused mitotic arrest and apoptosis induction in various human cancer cell lines.1?It was later found to be a potent inhibitor (IC50?= 100nM) of BET family member BRD4 and able to potently suppress c-Myc expression in MM.1S multiple myeloma cells.3?BI 2536 destabilizes N-Myc by inhibiting the deactivation of the ubiquitin E3 ligase Fbw7 by Plk1.4
BI 2536 is a PLK1 inhibitor, inducing apoptosis together with micro-tubule-destabilizing drugs in preclinical rhabdomyosarcoma models. Anti-cancer and potent PLK1 inhibitor.
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H302 |
| Precautionary statements | P280-P305+P351+P338 |
